Glenmark Pharmaceuticals Inc., USA announced the launch of 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial, set for distribution starting November 2025, which is bioequivalent to Abbott's product that had annual sales of approximately $63.8 million.